DIAMEDICA THERAPEUTICS ($DMAC) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.18 per share, beating estimates of -$0.18 by $0.00. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $DMAC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DIAMEDICA THERAPEUTICS Hedge Fund Activity
We have seen 27 institutional investors add shares of DIAMEDICA THERAPEUTICS stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 273,395 shares (+269.5%) to their portfolio in Q4 2024, for an estimated $1,484,534
- COOPERMAN LEON G added 113,261 shares (+7.5%) to their portfolio in Q4 2024, for an estimated $615,007
- VANGUARD GROUP INC added 109,360 shares (+8.8%) to their portfolio in Q1 2025, for an estimated $414,474
- PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE added 85,216 shares (+16.6%) to their portfolio in Q1 2025, for an estimated $322,968
- 683 CAPITAL MANAGEMENT, LLC added 76,116 shares (+inf%) to their portfolio in Q4 2024, for an estimated $413,309
- GOLDMAN SACHS GROUP INC added 52,854 shares (+76.7%) to their portfolio in Q1 2025, for an estimated $200,316
- MILLENNIUM MANAGEMENT LLC added 51,139 shares (+151.8%) to their portfolio in Q4 2024, for an estimated $277,684
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
